Amine Sena AYDIN, Tuba Rümeysa SİVRİ, Halise İnci GÜL

40124

Obesity and Obesity-Related Diseases and Treatments

Obesity and Obesity-Related Diseases and Treatments

Obesity is a disease that impairs body health as a result of abnormal or excessive fat deposit in the adipose tissue. Obesity and overweight are caused when the amount of energy taken during nutrition is higher than the amount spent during metabolism and physiological activities. Obesity is a chronic and common disease with increasing prevalence worldwide affecting both adults and children. Obesity is a multifactorial disease affected by many environmental and genetic factors and is known to be an important risk factor for early mortality, metabolic, and cardiovascular complications. The fact that obesity treatment is a long and difficult process and its cost is high emphasizes the importance of preventing obesity. For this purpose, obesity prevention studies including diet education, physical activity, and behavioral changes should be initiated and carried out. When preventive measures are insufficient, different treatment options come to the fore including diet, exercise, lifestyle changes, medication, and surgery. In this article, data on the definition of obesity, its causes, and treatment options have been compiled in order to determine the ideal methods for the prevention and treatment of obesity.
Keywords:

Anti-obesity agents drug, obesity, obesity treatment,

PDF

___

  • 1. Ünlü TN, Deniz D. Türkiye’de uygulanan obezite politikaları; Almanya uygulama karşılaştırılması. Selçuk Sağlık Derg. 2022;3(1):62-78.
  • 2. Yüksel E, Adiyaman F, Keçeli D, ve ark. Obezite konusu basında nasıl çerçevelenmektedir? Selçuk İletişim. 2014;8(2):149-176.
  • 3. Balli E. (2013). Obezite, obezitenin tetiklediği hastalıklar ve tedavileri. TC Erciyes Üniversitesi, Eczacılık Fakültesi Farmasötik Kimya Anabilim Dalı, Kayseri.
  • 4. Mutch DM, Clément K. Genetics of human obesity. Best Pract Res Clin Endocrinol Metab. 2006;20(4):647-664. [CrossRef]
  • 5. Malik VS, Willett WC, Hu FB. Global obesity: trends, risk factors and policy implications. Nat Rev Endocrinol. 2013;9(1):13-27. [CrossRef]
  • 6. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLOS Med. 2009;6(4):e1000058. [CrossRef]
  • 7. Steinbeck KS, Lister NB, Gow ML, Baur LA. Treatment of adolescent obesity. Nat Rev Endocrinol. 2018;14(6):331-344. [CrossRef]
  • 8. Kose O, Canakci V, Arabaci T, Saglam E. Obesity and periodontitis. Clin Exp Health Sci. 2012;2(2):89.
  • 9. Safaei M, Sundararajan EA, Driss M, Boulila W, Shapi'i A. A systematic literature review on obesity: understanding the causes & consequences of obesity and reviewing various machine learning approaches used to predict obesity. Comput Biol Med. 2021;136:104754. [CrossRef]
  • 10. Reinehr T. Obesity and thyroid function. Mol Cell Endocrinol. 2010;316(2):165-171. [CrossRef]
  • 11. Bays HE, González-Campoy JM, Bray GA, et al. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther. 2008;6(3):343-368. [CrossRef]
  • 12. Farooqi IS. Genetic and hereditary aspects of childhood obesity. Best Pract Res Clin Endocrinol Metab. 2005;19(3):359-374. [CrossRef]
  • 13. Clement K, Boutin P, Froguel P. Genetics of obesity. Am J Pharmacogenomics. 2002;2(3):177-187. [CrossRef]
  • 14. Turconi G, Guarcello M, Maccarini L, Bazzano R, Zaccardo A, Roggi C. BMI values and other anthropometric and functional measurements as predictors of obesity in a selected group of adolescents. Eur J Nutr. 2006;45(3):136-143. [CrossRef]
  • 15. Mohajan D, Mohajan HK. Obesity and its related diseases: a new escalating alarming in global health. J Innov Med Res. 2023;2(3):12- 23. [CrossRef]
  • 16. Oppert JM, Ciangura C, Bellicha A. Physical activity and exercise for weight loss and maintenance in people living with obesity. Rev Endocr Metab Disord. 2023:1-13. [CrossRef]
  • 17. Erem C. Prevalence of overweight and obesity in Turkey. IJC Metab Endocr. 2015;8:38-41. [CrossRef]
  • 18. Kim KB, Shin YA. Males with obesity and overweight. J Obes Metab Syndr. 2020;29(1):18-25. [CrossRef]
  • 19. WHO. WHO European Regional Obesity Report 2022. Geneva: World Health Organization. Regional Office for Europe; 2022.
  • 20. Düzgun-Öncel B, Karaoğlan D. Determinants of childhood obesity: evidence from Turkey. In Academic Studies, 2019:193.
  • 21. James WPT, Jackson-Leach R, Mhurchu CN, et al. Overweight and obesity (high body mass index). Comparative quantification of health risks: global and regional burden of disease attributable to selected major risk factors. 2004;1:497-596.
  • 22. Kyrou I, Randeva HS, Tsigos C, Kaltsas G, Weickert, MO. Clinical problemscaused by obesity. In Endotext, eds KR, Feingold, KR, Anawalt, B, Boyce A, et al. South Dartmouth, MA: MDText.com, Inc, 2018.
  • 23. Karataş S, Obez HN, Obeziteye Yönelik OKB. Tutumları ve yaşam kalitelerinin karşılaştırılması: Niteliksel çalışma. Acıbadem Univ Sağlık Bilimleri Derg. 2020;4:589-595.
  • 24. Blüher M, Aras M, Aronne LJ, et al. New insights into the treatment of obesity. Diabetes Obes Metab. 2023;25(8):2058-2072. [CrossRef]
  • 25. Alexander L, Christensen SM, Richardson L, et al. Nutrition and physical activity: an obesity medicine association (OMA) clinical practice statement 2022. Obes Pillars. 2022;1:100005. [CrossRef]
  • 26. Wiechert M, Holzapfel C. Nutrition concepts for the treatment of obesity in adults. Nutrients. 2021;14(1):169; Recent Advances and Remaining Challenges. 2021:1.
  • 27. Hensrud DD. Diet and obesity. Curr Opin Gastroenterol. 2004;20(2):119-124. [CrossRef]
  • 28. Takahashi T, Kohzuki M. Effect of weight loss and exercise therapy on obesity-related respiratory disorders. Asian J Hum Serv. 2019;17:95- 106. [CrossRef]
  • 29. Kahraman MS, Güriz SO, Özdel K. Yetişkinlerde obezite: Biyolojik veNpsikolojik tedaviler için genel bir gözden geçirme. Klin Psikiyatr Derg. 2014;17(1).28-40.
  • 30. Burke LE, Wang J, Sevick MA. Self-monitoring in weight loss: a systematic review of the literature. J Am Diet Assoc. 2011;111(1):92-102. [CrossRef]
  • 31. Wadden TA, Tronieri JS, Butryn ML. Lifestyle modification approaches for the treatment of obesity in adults. Am Psychol. 2020;75(2):235- 251. [CrossRef]
  • 32. Haywood C, Sumithran P. Treatment of obesity in older persons—a systematic review. Obes Rev. 2019;20(4):588-598. [CrossRef]
  • 33. Berberoğlu Z, Hocaoglu C, Sorunu KS. Küresel sağlık sorunu ‘obezite’: Güncel bir gözden geçirme. Celal Bayar Univ Sağlık Bilimleri Enstitüsü Derg. 2021;8(3):543-552. [CrossRef]
  • 34. Montan PD, Sourlas A, Olivero J, Silverio D, Guzman E, Kosmas CE. Pharmacologic therapy of obesity: mechanisms of action and cardiometabolic effects. Ann Transl Med. 2019;7(16):393. [CrossRef]
  • 35. Jackson VM, Breen DM, Fortin JP, et al. Latest approaches for the treatment of obesity. Expert Opin Drug Discov. 2015;10(8):825-839. [CrossRef]
  • 36. Kaplan LM. Pharmacologic therapies for obesity. Gastroenterology Clinics of North America. 2010;39(1):69-79. [CrossRef]
  • 37. Kayar H, Semra U. Çağımızın hastalığı obezite ve tedavisi. Mersin Univ Sağlık Bilimleri Derg. 2013;6(2):1-8.
  • 38. Williams DM, Nawaz A, Evans M. Drug therapy in obesity: a review of current and emerging treatments. Diabetes Ther. 2020;11(6):1199- 1216. [CrossRef]
  • 39. James PT, Leach R, Kalamara E, Shayeghi M. The worldwide obesity epidemic. Obes Res. 2001;9(suppl 4):228S-233S. [CrossRef]
  • 40. Harvey EL, Glenny AM, Kirk SF, Summerbell CD. An updated systematic review of interventions to improve health professionals’ management of obesity. Obes Rev. 2002;3(1):45-55. [CrossRef]
  • 41. Sumithran P, Proietto J. Benefit-risk assessment of orlistat in the treatment of obesity. Drug Saf. 2014;37(8):597-608. [CrossRef]
  • 42. Kosmalski M, Deska K, Bąk B, Różycka-Kosmalska M, Pietras T. Pharmacological support for the treatment of obesity—present and future. Healthcare (Basel). 2023;11(3):433. [CrossRef]
  • 43. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical in the prevention of diabetes in obese subjects (XENDOS) study. A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Clin Diabetol. 2004;5(2):95-104.
  • 44. McElroy SL, Hudson JI, Capece JA, et al. Topiramate for the treatment of binge eating disorder associated with obesity: a placebo-controlled study. Biol Psychiatry. 2007;61(9):1039-1048. [CrossRef]
  • 45. Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med. 2005;142(7):532-546. [CrossRef]
  • 46. Haddock CK, Poston WS, Dill PL, Foreyt JP, Ericsson M. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord. 2002;26(2):262-273. [CrossRef]
  • 47. Singh AK, Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of antiobesity drugs. Expert Rev Clin Pharmacol. 2020;13(1):53-64.
  • 48. Nuffer WA, Trujillo JM. Liraglutide: a new option for the treatment of obesity. Pharmacotherapy. 2015;35(10):926-934. [CrossRef]
  • 49. Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized place bo-co ntrol led-p hase 3 study. Fertil Steril. 2022;118(2):371-381. [CrossRef]
  • 50. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab. 2021;23(2):581-588. [CrossRef]
  • 51. Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6(1):18904. [CrossRef]
  • 52. Da Porto A, Casarsa V, Colussi G, Catena C, Cavarape A, Sechi L. Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: a pilot study. Diabetes Metab Syndr. 2020;14(4):289- 292. [CrossRef]
  • 53. Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362. [CrossRef]
Pharmata-Cover
  • Başlangıç: 2021
  • Yayıncı: Atatürk Üniversitesi
Arşiv
Sayıdaki Diğer Makaleler

Development and Validation of HPLC-UV Method for Determination of Meloxicam in Tablet Dosage Formulation

Reyhan Sıla ÇELİK, Burak BAYRAK, Yücel KADIOĞLU

Obesity and Obesity-Related Diseases and Treatments

Amine Sena AYDIN, Tuba Rümeysa SİVRİ, Halise İnci GÜL

Gut Microbiota and Its Importance for Our Health

Berkay BİLGİN, Hayrunisa HANCI

Effect of Tryptanthrin Compound on Lipop olysa cchar ide-I nduce d Inflammation Model in L929 Cell Line

Mehmet YILMAZ, Zerrin KUTLU